Careers Open Positions Benefits Contact Us Menu ALEXZA PHARMACEUTICALS PIPELINE Innovation in progress Commercial product ADASUVE® Staccato® loxapine For the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Full prescribing information, including boxed warning, at ADASUVE.com or the EMA website. Preclinical Phase 1 Phase 2 Phase 3 NDA/MAA Marketed Active programs in development with partners Staccato® alprazolam For the acute treatment of epileptic seizures Preclinical Phase 1 Phase 2 Phase 3 NDA/MAA Marketed Active programs led by Alexza Staccato® apomorphine For the rapid, acute treatment of OFF episodes in patients with Parkinson’s disease on stable anti-Parkinson medication Preclinical Phase 1 Phase 2 Phase 3 NDA/MAA Marketed Staccato® granisetron For the acute treatment of cyclic vomiting syndrome Preclinical Phase 1 Phase 2 Phase 3 NDA/MAA Marketed Inactive programs Staccato® zaleplon For the treatment of middle of the night awakening Preclinical Phase 1 Phase 2 Phase 3 NDA/MAA Marketed Migraine Preclinical Phase 1 Phase 2 Phase 3 NDA/MAA Marketed Smoking cessation Preclinical Phase 1 Phase 2 Phase 3 NDA/MAA Marketed For more information about our programs click here. For more information about pipeline opportunities click here. To discuss partnership and licensing opportunities, please contact our Business Development Group. ©2021 ALEXZA® ALEXZA PHARMACEUTICALS Corporate Headquarters 2091 Stierlin Court Mountain View, CA 94043 TEL: 650 944 7000 FAX: 650 944 7999 About Pipeline Partnering Contact Us Privacy Policy Terms of Use Disclaimer Staccato OBT